Clinical trials: TACE
Hepatic Tumor
Impact of New Interventional Imaging Modality Use on Patient Radiation Exposure in Transarterial Chemoembolization
Transarterial chemoembolization (TACE) is the most performed endovascular interventional radiology (IR) procedure. TACE procedures are performed in an IR suite, most of which are equipped with floor-based flat-panel robotic C-arm…
- Trial name
- NCT03698643
- Where
- France
- Volunteers
- 145 people
- Sponsor
- University Hospital, Montpellier
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Unresectable Hepatocellular Carcinoma
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy
The goal of this clinical trial is to learn if donafenib combined with or without immunotherapy and local therapy works to treat unresectable hepatocellular carcinoma that has failed in previous therapy.
- Trial name
- NCT06496815
- Testing
- Donafenib, transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy, PD-1,PD-L1
- Volunteers
- 32 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases).
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
- Trial name
- NCT04728633
- Testing
- Carmustine, Ethiodized Oil, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Thomas Jefferson University
Carcinoma, Hepatocellular
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
- Trial name
- NCT06205732
- Testing
- Immunotherapy, targeted therapy.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qianfoshan Hospital
Hepatocellular Carcinoma by BCLC Stage
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond…
- Trial name
- B-TACE (NCT05883176)
- Testing
- Bevacizumab Biosimilar QL 1101
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm, multi-center exploratory study.The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and…
- Trial name
- Toripalimab (NCT04926532)
- Testing
- Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Although it is commonly accepted that antiviral therapy should be commenced before or during hepatocellular carcinoma (HCC) treatment if the patients have high viral loads and elevated ALT or total bilirubin values with signs of…
- Trial name
- NCT01894269
- Testing
- Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma
D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT06643208
- Testing
- TACE-HAIC, Envafolimab and Lenvatinib
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma, Liver Cancer
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma
Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma.
- Trial name
- IDADOX (NCT06114082)
- Testing
- IDA-TACE, DOX-TACE
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular Carcinoma
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
To clarify the safety and efficacy of using uniform-sized drug-loaded embolic microspheres (E-TACE) of different particle sizes for graded embolization during TACE combined with Donafenib in the treatment of unresectable primary…
- Trial name
- NCT07180459
- Testing
- E-TACE, Donafenib
- Where
- 10 sites in China
- Volunteers
- 118 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma Non-resectable
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
The vast majority of primary liver cancer (90%) is hepatocellular carcinoma (HCC), and the majority of HCC patients have been locally advanced or metastatic disease when they are diagnosed in clinics.
- Trial name
- PLTHCC (NCT04273100)
- Testing
- PD-1 mAb combined with TACE and lenvatinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Heptocellular Cancer, Biliary Tract Neoplasms
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Background: Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer.
- Conditions
- Heptocellular Cancer, Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT01853618
- Testing
- Tremelimumab, RFA, TACE
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .
- Trial name
- NCT03510416
- Testing
- Apatinib, TACE
- Volunteers
- 22 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Hepatocellular Carcinoma
Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC.
- Trial name
- NCT06470256
- Testing
- Palliative Hepatectomy, Durvalumab, Lenvatinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhiyong Huang
Hepatocellular Carcinoma
Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
Transcatheter arterial chemoembolization (TACE) is recommended as the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) (i.e., BCLC stage B).
- Trial name
- BEST (NCT06090656)
- Testing
- Bevacizumab combined with Sintilimab, Transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
- Trial name
- HCC (NCT03398122)
- Testing
- TACE, Apatinib
- Where
- China
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Enhanced Recovery After Surgery, Multimodal Analgesia
Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma
To evaluate the effectiveness of the combination of hydrochloride hydromorphone and flurbiprofen ester for post-TACE intravenous patient-controlled intravenous analgesia (PCIA).
- Conditions
- Enhanced Recovery After Surgery, Multimodal Analgesia, Real-world Study, Transarterial Chemoembolization
- Trial name
- NCT07315022
- Testing
- hydrochloride hydromorphone + flurbiprofen axetil, conventional analgesia
- Where
- China
- Volunteers
- 129 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University